Human Influenza Clinical Trial
Official title:
Prevention of Secondary Transmission of Human Influenza by Promoting Handwashing With Soap: The Bangladesh Interruption of Secondary Transmission of Influenza Study (BISTIS)
The next influenza pandemic is expected to spread rapidly in resource-poor settings.
Influenza viruses spread from human-to-human via large respiratory droplets. Transmission
via large-particle respiratory droplets is believed to be mediated by close contact between
infected and susceptible persons or contact with droplet-contaminated fomites. Close contact
between infected and susceptible persons may consist of skin-to-skin contact (e.g., via
hands) or inhalation of respiratory droplets (e.g., due to talking, coughing, or sneezing by
the infected person). Airborne transmission, which is expected to result in transmission
over long distances (>1 meter) and which would be mediated by ventilation, is believed to be
uncommon. Therefore, the greatest risk of transmission from personal contact comes from
those people who are closest to an index case, such as contacts living in the same
household. There are, to date, no published estimates of the secondary attack ratio of
influenza among household contacts of index case-patients in low-income countries. Moreover,
the investigators do not have data on the risk factors for secondary transmission of
influenza from index case-patients to their household contacts. There is some data for the
benefits of promoting handwashing with soap on the risk of all-cause acute respiratory
illness among children < 15 years old in a resource-poor setting in Pakistan. But, the
investigators do not have evidence that promoting handwashing with soap will acutely reduce
the risk of secondary transmission. Therefore, the investigators propose to conduct a study
in rural Bangladesh to assess the following:
- The secondary attack ratio of influenza among household contacts of an index
case-patient with influenza
- The risk factors for secondary transmission of influenza from an index case-patient to
household contacts
- The impact of promoting handwashing with soap on the risk of secondary transmission of
influenza from an index case-patient to household contacts
- The impact of handwashing promotion on handwashing behavior six months after
intervention
- The impact of handwashing promotion on the prevalence of respiratory infections,
diarrhea and influenza
BISTIS builds on hospital-based surveillance for Influenza virus infection, which is ongoing
in hospitals around Bangladesh, as part of the Hospital-based Influenza Surveillance (HBIS)
and Surveillance for the Epidemiology of Influenza in Bangladesh (SEIB) projects. We intend
to recruit patients identified at the Jahurul Islam Medical College Hospital in Kishoregonj,
Bangladesh, where both HBIS and SEIB are in place. In this hospital 80% of all the patients
who present with influenza-like illness (ILI) to the outpatient departments of Medicine and
Pediatrics are from three upazillas of Kishorgonj district: Bajitpur, Kuliar char and
Kotiadi. The distances of these three upazillas are within 30 minutes travel time from
Jahurul Islam Medical College Hospital (one way) and hence these upazillas will serve as the
primary catchment areas for BISTIS. The table below illustrates the number of ILI cases
identified through HBIS and SEIB study at Jahurul Islam Medical College Hospital in 2008 and
also the number and proportion among them who were tested PCR positive for influenza virus.
n.b., most influenza-positive specimens were collected between May and September in 2007 and
2008
We will also enroll patients who present to two local upazilla health complexes (UHCs), one
in Bajitpur and one in Kuliar Char. These local health complexes see numerous patients a day
from the rural areas surrounding the clinic. Patients who present to these clinics are more
likely to have symptom onset within 24 hours of presentation then those patients who seek
care at JIMCH, since patients may only want to go to the hospital if their illness has been
severe and prolonged over several days. Some studies on the impact of handwashing promotion
have found that the intervention is effective if delivered within 36 hours of the index
case-patient's symptom onset; therefore, the UHC sites are appropriate for enrollment of
patients for BISTIS in addition to enrollment at JIMCH.
Lastly, we will recruit patients from pharmacies within the catchment areas mentioned above.
By collaborating with local pharmacists, we intend on further increasing our enrollment
numbers. Patients who present to local pharmacists are likely to have symptom onset within
24 hours of their visit to the pharmacist and are also more likely to be the primary case
within their bari.
Specific Aim 1: To measure the secondary attack ratio (SAR) of influenza viruses among
household contacts of index cases with influenza, in a rural setting in Bangladesh
Methods for Specific Aim 1
Specimen collection and processing A trained study physician will procure a nasal swab and
an oropharyngeal swab from consenting index case-patients meeting the inclusion criteria
above using a standardized method. At the Jahurul Islam Medical College Hospital, the nasal
and oropharyngeal swabs will both be placed into a single tube containing viral transport
media (VTM). An aliquot of the VTM will then be tested for Influenza A and B by the trained
physician or nurse using a rapid antigen detection test (QuickVue® Influenza A + B). If the
QuickVue® result is positive for Influenza A or Influenza B, the remaining VTM will be kept
at 4°C. All VTM will be transported to the ICDDR,B virology laboratory in Dhaka on a weekly
basis. At the ICDDR,B virology laboratory, RT-PCR testing for Influenza A (H1N1), Influenza
A ( H3N2), and Influenza B will be carried out. If Influenza A H1N1 and A H3N2 are both
negative, RT-PCR testing for Influenza A H5N1 will be performed. If the QuickVue® result is
negative for both Influenza A and Influenza B, the patient will be informed of the result
and thanked for participating in the study. The VTM will be discarded using appropriate
infection control procedures, unless the patient is also participating in the ongoing HBIS
or SEIB (in which case the remaining specimen will be processed like other surveillance
specimens).
Enumeration of bari contacts and questionnaire administration Illness tracking among bari
contacts Illness tracking will be carried out on each day for 10 days until after resolution
of the index case-patient's illness. Resolution will be defined as the lack of fever, cough,
and sore throat for at least 24 hours preceding the FRA's daily illness tracking visit.
Thus, if the index case-patient's illness resolves on day 4 after enrollment, illness
tracking will continue until day 14 after enrollment. The FRA will visit the patient's home
and record information regarding the presence or absence of ILI and SARI symptoms in each
household contact using an individual illness tracking form (appendix 9a8a and 9b8b -
illness tracking form, ages ≥ 5 and < 5). For the purposes of screening household contacts
for influenza, we will alter the age-specific case definition for children, based on data
from urban Bangladesh, which demonstrates that fever and rhinorrhea are the most predictive
factors for influenza in children < 5 years old (WA Brooks, ICDDR,B, personal
communication).
If a household contact meets the age-specific case definition and does NOT have any danger
signs, the FRA will obtain written informed consent for specimen collection (appendix 2-
specimen collection from household contact for adult > 18 years old, (appendix 3 - specimen
collection from household contact for child < 18 years old). The FRA will alert the medical
officer, who will visit the home with the FRA no later than the following day in order to
collect nasal and oropharyngeal swabs from the ill household contact. She will immediately
place both swabs into VTM, which will then be placed into a cool box, containing ice and a
thermometer to ensure temperatures < 40 C.
All specimens collected in the field will be placed in a cool box and transported to the
ICDDR,B laboratory within 72 hours. At the ICDDR,B virology laboratory, all specimens for
household contacts will be tested using RT-PCR for Influenza A (H1N1), A (H3N2), and
Influenza B (and A (H5N1) if appropriate).
Illness tracking among household contacts will continue in each household until the 10th
full day following the resolution of the index case-patient's symptoms, irrespective of
whether any household contact develops illness or not.
Specific Aim 2: To test the efficacy of a handwashing promotion intervention for prevention
of intrahousehold transmission of influenza virus
Methods for Specific Aim 2
To address this specific aim, we will conduct a randomized controlled trial. Households of
index case-patients with influenza-like illness who are recruited at Jahurul Islam Medical
College Hospital the UHCs or the local pharmacies will be randomized to the intervention
group or the routine practices group.
The two groups will be defined as:
- Intervention Households: intensive promotion of handwashing with soap, and provision of
facilitating tools, to the index-case-patient and all available household contacts
- Routine practices Households: continuation of the household's usual handwashing and
respiratory hygiene practices group.
For promotion of handwashing with soap to intervention households, Field Intervention
Specialists (FIS) will be trained to carry out a structured intervention that will follow
constructs of Social Cognitive Theory (SCT). SCT addresses the reciprocal interaction
between individuals, their environment, and health behaviors. Given that intervention will
occur at the bari level, group-mediated constructs such as observational learning and
reinforcements are highly relevant. FISs will visit the intervention households on a daily
basis for 10 days after the resolution of the index case-patient's illness in order to
encourage handwashing with soap at the recommended times. Routine practices households will
also be exposed to the intervention, but only upon completion of the study. As noted above,
under Specific Aim 1, an FRA will visit the home of the index case-patient daily for 10 days
after the resolution of the index case-patient's symptoms in order to record age-specific
case defining symptoms.
Specific aim 3: To identify risk factors, other than handwashing with soap, for
intrahousehold transmission of influenza in a rural setting in Bangladesh.
Methods for Specific Aim 3
To address Specific Aim 3, we will conduct a nested cohort study to assess risk factors for
intrahousehold transmission of influenza viruses. Here, the cohort under investigation is
the routine practices group, as defined under Specific Aim 2. All data required to address
this Specific Aim 3 will have been collected as part of the data collection described above
under Specific Aim 1.
A case will be defined as: RT-PCR confirmed Influenza virus infection (A or B) in a
household contact of an RT-PCR confirmed Influenza virus infection (A or B) index
case-patient during 10 days of follow-up after resolution of the index case-patient's
symptoms.
Specific aim 4: To assess whether exposure to the BISTIS intervention results in sustained
improvements in handwashing behavior.
Methods for Specific Aim 4
To address Specific Aim 4, we will visit each bari that was enrolled in the intervention
study 4 - 7 months after illness tracking is complete. The FRA will measure handwashing
behavior at the bari. We will complete a structured observation of the bari's common
handwashing behaviors. One or two months after the initial follow-up visit, the FRA will
return to the bari and once again collect the same information on the handwashing behavior
but will also provide soap to the bari. The FRA will collect the soap two days later. Data
from the soap will be used to calculate the number of soap use events in the bari. In total
an FRA will visit the household a total of three times, two visits for data collection and
one visit to collect the soap.
Specific aim 5: To assess if exposure to the BISTIS intervention results in a reduced risk
of respiratory infections, diarrhea, and influenza.
Methods for Specific Aim 5
The measurements of the health outcomes will be done in two different ways. At the first
visit, after the handwashing behavior information is collected, the FRA will record whether
each member of the bari has had symptoms of fever, cough, sore throat, difficulty breathing,
respiratory illness or diarrhea in the previous 48 hours. At the third visit, in April 2010,
the FRA will record mobile phone numbers of two or three bari members. The FRA will identify
a key informant, who will be able to provide information regarding fever in any bari member.
The FRA will phone the bari once each week during the influenza season and speak with the
key informant once per week to assess whether any bari member has had fever during the
previous 24 hours. If any member is reported to have a fever, we will dispatch an MO or
lab/medical technician to the bari to obtain nasopharyngeal swab from that member for flu
testing by PCR. A case will be defined as: RT-PCR confirmed Influenza virus infection (A or
B).
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01690637 -
Panama and El Salvador Children's Oseltamivir Study
|
Phase 4 | |
Completed |
NCT03572491 -
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
|
Phase 3 | |
Recruiting |
NCT04487041 -
Tfh Dysfunction in HIV and Aging
|
Phase 4 | |
Completed |
NCT02387294 -
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
|
Phase 3 | |
Completed |
NCT02600585 -
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults
|
N/A | |
Completed |
NCT01511744 -
Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine
|
Phase 4 | |
Completed |
NCT02398097 -
Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects
|
Phase 4 | |
Completed |
NCT01342796 -
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
|
Phase 2 | |
Completed |
NCT01677702 -
Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization
|
N/A | |
Active, not recruiting |
NCT01096225 -
Immunogenicity Study of S-OIV H1N1 Influenza Vaccine
|
N/A | |
Completed |
NCT01879553 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
|
Phase 2 | |
Completed |
NCT01879540 -
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
|
Phase 2 | |
Completed |
NCT01651104 -
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
|
Phase 2 | |
Completed |
NCT01636102 -
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
|
Phase 2 | |
Completed |
NCT03448705 -
Safety of 4Fluart ID Suspension for Injection in Adult Subjects
|
Phase 1 | |
Completed |
NCT02478905 -
Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting
|
N/A | |
Recruiting |
NCT04431050 -
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
|
||
Completed |
NCT01568788 -
Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine
|
N/A | |
Completed |
NCT05155319 -
Universal Influenza A Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT01880697 -
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
|
Phase 3 |